|
Post by alethea on Jan 11, 2016 11:39:50 GMT -5
At this point I just want to break even and get out of this mess. Any chance of us hitting $7.5 by next month??? I hope you are joking. If you are serious, the answer is of course NO.
|
|
|
Post by rch51 on Jan 11, 2016 11:43:35 GMT -5
Matt is the right guy to head up the show going forward because his primary responsibility will be to see the company through a partial sale or a series of sales. First and foremost he is a bean counter, a competent one at that. Al trusts him. He can make more money for essentially doing what he is already doing. The company needs to wind down without a BK. Matt's probably as good a choice as anyone for that purpose. I wouldn't be surprised at all if the company already has suitors lined up and it's simply a matter of finding the right number.
I can think of no logical scenario in which the company works its way through this without a highly unlikely White Knight or a significant cash upfront TS deal or of course an outright sale of Afrezza and TS. It may not be as dire as many believe. Disheartening though, for sure.
|
|
|
Post by factspls88 on Jan 11, 2016 11:44:41 GMT -5
Any guesses why they picked Matt as the replacement? It seems strange to me since Al took over when Hakkan was removed. Because they didn't have anybody else.
|
|
|
Post by mindovermatter on Jan 11, 2016 11:51:35 GMT -5
Now we know why Matt sounded so flustered last Tuesday when it was him and not Duane giving the call. He knew that Duane was probably not going to be the CEO due to the legal issues.
|
|
|
Post by alethea on Jan 11, 2016 11:52:05 GMT -5
I hate penny stocks...and now I own one! I was really looking forward to hearing the new CEO speak. Grrr Those non compete usually don't stand up in court, though he would have lost the benefits. The only way I can read this, is he backed out. Really really bad news for MNKD shareholders. DeSisto backed out. No doubt about it. I think he thought Sanofi wanted to acquire 100% of Afrezza and maybe even MNKD. He thought he was being hired to negotiate the best buy-out by Sanofi. He found out on January 5th (like the rest of us) that Sanofi wasn't kidding about walking away for good. He is smart enough to know that it is now truly over. They have to sell the Company or AT LEAST Afrezza, pretty goddamn quick. We'll be lucky to $2 per share. I will hang on in hopes of getting that or more.
|
|
|
Post by mnholdem on Jan 11, 2016 11:55:22 GMT -5
If I were Patrick Sullivan, President & CEO of Insulet, and I had been reading testimonial blogs from early adopters about how Afrezza may wind up putting insulin pumps out of business, I don't think that I'd hesitate to threaten MannKind with a multi-$million (if not a $billion) lawsuit if I had that card in my hand.
I cannot think of any of the big players in the diabetes treatment industry who will benefit by Afrezza doing well or who want it to succeed.
|
|
|
Post by bradleysbest on Jan 11, 2016 11:59:32 GMT -5
I believe Matt was selected as CEO so they do not have to pay another executive salary while they TRY & sell the company. Just my .02
|
|
|
Post by dictatorsaurus on Jan 11, 2016 12:00:29 GMT -5
Exactly what would have DD done differently?
Afrezza/Mannkind needs to be bought out. We are well beyond the partnership crap at this point. Not enough time or money to drag this out.
|
|
|
Post by dictatorsaurus on Jan 11, 2016 12:01:35 GMT -5
|
|
|
Post by nuklerfizzacist on Jan 11, 2016 12:03:04 GMT -5
I hate penny stocks...and now I own one! I was really looking forward to hearing the new CEO speak. Grrr Those non compete usually don't stand up in court, though he would have lost the benefits. The only way I can read this, is he backed out. Really really bad news for MNKD shareholders. DeSisto backed out. No doubt about it. I think he thought Sanofi wanted to acquire 100% of Afrezza and maybe even MNKD. He thought he was being hired to negotiate the best buy-out by Sanofi. He found out on January 5th (like the rest of us) that Sanofi wasn't kidding about walking away for good. He is smart enough to know that it is now truly over. They have to sell the Company or AT LEAST Afrezza, pretty goddamn quick. We'll be lucky to $2 per share. I will hang on in hopes of getting that or more. No offense but that sure is alot of inside the mind of D.DeSisto stuff. Could be the case but I'm no mind reader, all i can go on is facts and intuition...right now saying he backed out makes whomever wrote that report a liar.
|
|
|
Post by humann on Jan 11, 2016 12:05:09 GMT -5
I believe Matt was selected as CEO so they do not have to pay another executive salary while they TRY & sell the company. Just my .02 To me, it is now safe to say that something changed between the time they hired Desisto and now. Worst case, no one expected Sanofi to back out; I was having a hard time believing that theory, but now seems more plausible. Alternatively, a deal has become imminent that makes compensation of a new CEO unnecessary. I hope it is not that they have just now decided to try and sell the company...
|
|
|
Post by mindovermatter on Jan 11, 2016 12:08:24 GMT -5
I believe Matt was selected as CEO so they do not have to pay another executive salary while they TRY & sell the company. Just my .02 To me, it is now safe to say that something changed between the time they hired Desisto to now. Worst case, no one expected Sanofi to back out; I was having a hard time believing that theory, but now seems more plausible. Alternatively, a deal has become imminent that makes compensation of a new CEO unnecessary. I hope it is not that they have just decided to try and sell the company, now... If there is any company that I'd love to see take Affrezza would be Novo Nordisk and pair it with Tresiba. I'd also love to see that combo put Sanofi out of the diabetes business as it takes all market share away from them. As far as I am concerned, Sanofi can go choke on a a frog leg.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 11, 2016 12:10:02 GMT -5
To me, it is now safe to say that something changed between the time they hired Desisto to now. Worst case, no one expected Sanofi to back out; I was having a hard time believing that theory, but now seems more plausible. Alternatively, a deal has become imminent that makes compensation of a new CEO unnecessary. I hope it is not that they have just decided to try and sell the company, now... If there is any company that I'd love to see take Affrezza would be Novo Nordisk and pair it with Tresiba. I'd also love to see that combo put Sanofi out of the diabetes business as it takes all market share away from them. As far as I am concerned, Sanofi can go choke on a a frog leg. Grass is always greener on the other side.. Novo is the worst partner as Novolog makes more $$$ to Novo than APidra to Sanofi...
|
|
|
Post by dictatorsaurus on Jan 11, 2016 12:10:10 GMT -5
To me, it is now safe to say that something changed between the time they hired Desisto to now. Worst case, no one expected Sanofi to back out; I was having a hard time believing that theory, but now seems more plausible. Alternatively, a deal has become imminent that makes compensation of a new CEO unnecessary. I hope it is not that they have just decided to try and sell the company, now... As far as I am concerned, Sanofi can go choke on a a frog leg. Frog leg dipped in cheese!
|
|
|
Post by humann on Jan 11, 2016 12:11:21 GMT -5
If there is any company that I'd love to see take Affrezza would be Novo Nordisk and pair it with Tresiba. I'd also love to see that combo put Sanofi out of the diabetes business as it takes al market share away from them. As far as I am concerned, Sanofi can go choke on a a frog leg. May be the most consolation we'll get.
|
|